Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes

LONDON, April 12, 2017 /PRNewswire/ — This new report builds on our 2014 Insight Pharma Report, Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies. In that report, we focused on the major classes of cancer immunotherapy drugs that were then emerging from academic and corporate research: immune checkpoint inhibitors, cancer vaccines, and adoptive‚Ķ